MX2022012685A - Compuestos específicos contra la proteína s de coronavirus y usos de los mismos. - Google Patents
Compuestos específicos contra la proteína s de coronavirus y usos de los mismos.Info
- Publication number
- MX2022012685A MX2022012685A MX2022012685A MX2022012685A MX2022012685A MX 2022012685 A MX2022012685 A MX 2022012685A MX 2022012685 A MX2022012685 A MX 2022012685A MX 2022012685 A MX2022012685 A MX 2022012685A MX 2022012685 A MX2022012685 A MX 2022012685A
- Authority
- MX
- Mexico
- Prior art keywords
- cov
- protein
- antibodies
- binding fragments
- coronaviruses
- Prior art date
Links
- 241000711573 Coronaviridae Species 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102100031673 Corneodesmosin Human genes 0.000 abstract 5
- 101710139375 Corneodesmosin Proteins 0.000 abstract 5
- 239000012634 fragment Substances 0.000 abstract 4
- 241001678559 COVID-19 virus Species 0.000 abstract 2
- 241000315672 SARS coronavirus Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Anticuerpos, y fragmentos de unión a antígeno de los mismos, que presentan especificidad de unión por la proteína S de coronavirus (CoV-S), tal como la proteína S del coronavirus del SARS (SARS-CoV-S) y/o la proteína S del coronavirus del SARS 2 (SARS-CoV-2-S), que incluyen anticuerpos neutralizantes y anticuerpos que se unen y/o que compiten por la unión a los mismos epitopes lineales o conformacionales en la CoV-S. También se divulgan conjugados de los anticuerpos anti-CoV-S, y fragmentos de unión de los mismos, conjugados a una o más unidades funcionales o detectables. Se contemplan asimismo métodos para elaborar dichos anticuerpos anti-CoV-S y fragmentos de unión a antígeno de los mismos. Otras formas de realización de la divulgación incluyen el uso de los anticuerpos anti-CoV-S, y fragmentos de unión de los mismos, para el diagnóstico, la evaluación y el tratamiento de enfermedades y trastornos asociados con coronavirus, o la proteína S de los mismos, y condiciones en las cuales una neutralización o inhibición de los coronavirus, o la proteína S de los mismos, serían beneficiosas terapéutica y/o profilácticamente.
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008545P | 2020-04-10 | 2020-04-10 | |
| US202063021589P | 2020-05-07 | 2020-05-07 | |
| US202063046313P | 2020-06-30 | 2020-06-30 | |
| US202063112122P | 2020-11-10 | 2020-11-10 | |
| US202163138886P | 2021-01-19 | 2021-01-19 | |
| US202163143456P | 2021-01-29 | 2021-01-29 | |
| US202163147495P | 2021-02-09 | 2021-02-09 | |
| US202163148754P | 2021-02-12 | 2021-02-12 | |
| US202163150413P | 2021-02-17 | 2021-02-17 | |
| US202163152054P | 2021-02-22 | 2021-02-22 | |
| US202163163400P | 2021-03-19 | 2021-03-19 | |
| PCT/US2021/026574 WO2021207597A1 (en) | 2020-04-10 | 2021-04-09 | Compounds specific to coronavirus s protein and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012685A true MX2022012685A (es) | 2023-03-08 |
Family
ID=78023132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012685A MX2022012685A (es) | 2020-04-10 | 2021-04-09 | Compuestos específicos contra la proteína s de coronavirus y usos de los mismos. |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US11192940B2 (es) |
| EP (1) | EP4132579A4 (es) |
| JP (1) | JP2023521418A (es) |
| CN (1) | CN116096412A (es) |
| BR (1) | BR112022020539A2 (es) |
| CA (1) | CA3179763A1 (es) |
| MX (1) | MX2022012685A (es) |
| TW (1) | TW202204397A (es) |
| WO (1) | WO2021207597A1 (es) |
| ZA (1) | ZA202212246B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023534923A (ja) | 2020-07-06 | 2023-08-15 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子 |
| EP4182687A2 (en) * | 2020-07-20 | 2023-05-24 | Bio-Rad Laboratories, Inc. | Immunoassay for sars-cov-2 neutralizing antibodies and materials therefor |
| JP2023540037A (ja) | 2020-08-26 | 2023-09-21 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子 |
| WO2022204202A1 (en) | 2021-03-23 | 2022-09-29 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| CN115594742A (zh) * | 2021-07-09 | 2023-01-13 | 复旦大学（Cn） | 一种冠状病毒s蛋白变体及其应用 |
| WO2023059900A2 (en) * | 2021-10-08 | 2023-04-13 | Invivyd, Inc. | Pharmaceutical formulations comprising anti-coronavirus s protein antibodies and uses thereof |
| EP4177266A1 (en) * | 2021-11-05 | 2023-05-10 | Katholieke Universiteit Leuven | Neutralizing anti-sars-cov-2 human antibodies |
| WO2023079137A1 (en) * | 2021-11-05 | 2023-05-11 | Katholieke Universiteit Leuven | Neutralizing anti-sars-cov-2 human antibodies |
| WO2023094980A1 (en) * | 2021-11-23 | 2023-06-01 | Fondazione Toscana Life Sciences | Antibodies to coronavirus |
| US20230257448A1 (en) * | 2022-01-03 | 2023-08-17 | Twist Bioscience Corporation | Bispecific sars-cov-2 antibodies and methods of use |
| WO2023131262A1 (zh) * | 2022-01-10 | 2023-07-13 | 杰库(上海)生物医药研究有限公司 | 特异性结合SARS-CoV-2的抗原结合蛋白 |
| CN116617388A (zh) * | 2022-01-26 | 2023-08-22 | 百奥泰生物制药股份有限公司 | 靶向冠状病毒的抗体在预防、治疗或改善covid-19中的应用 |
| WO2023150771A2 (en) * | 2022-02-07 | 2023-08-10 | Obi Pharma, Inc. | Pharmaceutical composition for treatment and prevention of coronavirus infection |
| WO2023215910A1 (en) | 2022-05-06 | 2023-11-09 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
| WO2024102674A1 (en) | 2022-11-13 | 2024-05-16 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009537143A (ja) * | 2006-05-19 | 2009-10-29 | アムゲン インコーポレイティッド | Ｓａｒｓコロナウイルスに対する抗体 |
| CN102088958A (zh) | 2008-07-10 | 2011-06-08 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 用于大分子的增强的递送的方法和组合物 |
| MX2017007242A (es) | 2014-12-05 | 2018-01-25 | Memorial Sloan Kettering Cancer Center | Receptores de antigeno quimerico que se dirigen al receptor acoplado a la proteina g y sus usos. |
| US10960070B2 (en) | 2016-10-25 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| EP3807210A4 (en) | 2018-06-13 | 2022-05-11 | The Scripps Research Institute | NANOPARTICULAR VACCINES WITH NOVEL STRUCTURAL COMPONENTS |
| WO2021148884A1 (en) | 2020-01-24 | 2021-07-29 | Tychan Pte. Ltd. | Anti-wuhan coronavirus antibodies |
| JP2023512684A (ja) | 2020-02-03 | 2023-03-28 | ヴィア・バイオテクノロジー・インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法 |
| WO2021156490A2 (en) | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
| BR112022016220A2 (pt) | 2020-02-14 | 2022-10-25 | Univ Washington | Polipeptídeos, composições e seu uso para tratar ou limitar o desenvolvimento de uma infecção |
| IL295801A (en) | 2020-02-26 | 2022-10-01 | Vir Biotechnology Inc | Antibodies against sars-cov-2 and methods of using them |
| CA3173701A1 (en) * | 2020-10-09 | 2022-04-14 | Jean-Pierre Sommadossi | Niran interfering drugs for sars-cov-2 mutant therapy |
| US20240025971A1 (en) * | 2020-10-23 | 2024-01-25 | Atreca, Inc. | Antibodies to coronavirus sars-cov-2 |
| WO2022204713A2 (en) * | 2021-03-26 | 2022-09-29 | Atreca, Inc. | Antibodies to sars-cov-2 |
-
2021
- 2021-04-09 JP JP2022562120A patent/JP2023521418A/ja active Pending
- 2021-04-09 WO PCT/US2021/026574 patent/WO2021207597A1/en unknown
- 2021-04-09 TW TW110112968A patent/TW202204397A/zh unknown
- 2021-04-09 CN CN202180043136.9A patent/CN116096412A/zh active Pending
- 2021-04-09 CA CA3179763A patent/CA3179763A1/en active Pending
- 2021-04-09 EP EP21784570.0A patent/EP4132579A4/en active Pending
- 2021-04-09 US US17/226,153 patent/US11192940B2/en active Active
- 2021-04-09 BR BR112022020539A patent/BR112022020539A2/pt not_active Application Discontinuation
- 2021-04-09 MX MX2022012685A patent/MX2022012685A/es unknown
- 2021-08-18 US US17/405,246 patent/US11220536B1/en active Active
- 2021-08-18 US US17/405,650 patent/US11414479B2/en active Active
- 2021-12-01 US US17/539,635 patent/US20220153815A1/en active Pending
-
2022
- 2022-11-09 ZA ZA2022/12246A patent/ZA202212246B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202204397A (zh) | 2022-02-01 |
| US20210388067A1 (en) | 2021-12-16 |
| US20220153815A1 (en) | 2022-05-19 |
| JP2023521418A (ja) | 2023-05-24 |
| US20220010002A1 (en) | 2022-01-13 |
| US11192940B2 (en) | 2021-12-07 |
| US11414479B2 (en) | 2022-08-16 |
| WO2021207597A1 (en) | 2021-10-14 |
| CN116096412A (zh) | 2023-05-09 |
| US20210324048A1 (en) | 2021-10-21 |
| ZA202212246B (en) | 2023-07-26 |
| BR112022020539A2 (pt) | 2023-04-25 |
| EP4132579A1 (en) | 2023-02-15 |
| EP4132579A4 (en) | 2024-05-22 |
| CA3179763A1 (en) | 2021-10-14 |
| US11220536B1 (en) | 2022-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012685A (es) | Compuestos específicos contra la proteína s de coronavirus y usos de los mismos. | |
| MX2018012470A (es) | Anticuerpos anti pacap humanizados y usos de ellos. | |
| WO2022170126A3 (en) | Compounds specific to coronavirus s protein and uses thereof | |
| MX2010003828A (es) | Anticuerpos especificos para la forma de protofibrillas de la proteina beta-amiloide. | |
| MX2011011445A (es) | Composiciones que contienen cannabinoides y metodos para su uso. | |
| WO2002082041A3 (en) | Production and use of novel peptide-based agents for use with bi-specific antibodies | |
| ATE390928T1 (de) | Zusammensetzungen zur behandlung von hauterkrankungen | |
| BRPI0516483A (pt) | preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade | |
| WO2008070593A3 (en) | Variant target binding agents and uses thereof | |
| MA31886B1 (fr) | Anticorps anti-hepcidine et utilisations de ceux-ci | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| ATE330967T1 (de) | An her2 bindende peptidverbindungen | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| WO2021239935A9 (en) | Neutralizing antibodies against sars-related coronavirus | |
| UA105630C2 (uk) | Нові антитіла, які використовуються при лікуванні раку | |
| EA200401081A1 (ru) | Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro | |
| WO2022167816A3 (en) | Antibodies | |
| CA2725873A1 (en) | Monoclonal antibodies to basic fibroblast growth factor | |
| MX2021011715A (es) | Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención. | |
| MX2020008663A (es) | Anticuerpos anti-angiopoyetina-2 y usos de los mismos. | |
| PH12020500417A1 (en) | Anti-efgr antibody drug conjugates (adc) and uses thereof | |
| WO2008070090A3 (en) | Compositions and methods for diagnosing and treating cancer | |
| MX2023002901A (es) | Anticuerpos que se unen a la proteína auxiliar del receptor de interleucina-1 (il1rap) y usos de estos. | |
| BR112023000455A2 (pt) | Tratamento de doença inflamatória que usa anticorpos de fator antitecidual | |
| SG148190A1 (en) | Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer |